Health & Fitness:Medicine
SABCS 2019: Tucatinib: A New Standard of Care for HER2-Positive Metastatic Breast Cancer?
2020-04-21
Download
Right click and do "save link as"
Dr. Rashmi Murthy, assistant professor of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston, discusses the results of the HER2CLIMB study that she presented at the 2019 San Antonio Breast Cancer Symposium showing that the experimental medicine tucatinib offers benefits to people diagnosed with HER2-positive metastatic breast cancer and may be a new standard of care.
Listen to the episode to hear Dr. Murthy explain:
- a summary of the study results
- why this study included people with brain metastases
- the side effects of tucatinib
- why she thinks the results are practice changing
More Episodes
Lymphedema 101
2021-04-30
2021-04-30
Scalp Cooling: How It Works to Preserve Hair
2021-03-26
2021-03-26
Update on COVID-19 Vaccines
2021-03-18
2021-03-18
Immunotherapy Side Effects
2021-03-12
2021-03-12
Talking to Your Doctor About Going Flat
2021-02-26
2021-02-26
Hypofractionated Radiation Therapy
2020-12-04
2020-12-04
Breast Cancer Research at ESMO 2020
2020-10-16
2020-10-16
Get this podcast on your
phone, FREE
